Natco Pharma's Q3 FY 2025-26 Quarterly Results
- 13 Feb 2026
Result Summary
- Natco Pharma Ltd reported a 51.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 8.3%.
- Its expenses for the quarter were down by 35.9% QoQ and up 11.7% YoY.
- The net profit decreased 70.8% QoQ and increased 14.3% YoY.
- The earnings per share (EPS) of Natco Pharma Ltd stood at 8.46 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 705.40 | 1463.00 | 651.10 | -51.8% | 8.3% |
Total Expenses | 544.30 | 849.30 | 487.40 | -35.9% | 11.7% |
Profit Before Tax | 161.10 | 613.70 | 163.70 | -73.7% | -1.6% |
Tax | 20.70 | 95.80 | 31.30 | -78.4% | -33.9% |
Profit After Tax | 151.30 | 517.90 | 132.40 | -70.8% | 14.3% |
Earnings Per Share | 8.46 | 28.94 | 7.43 | -70.8% | 13.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Natco Pharma Ltd is a well-established entity in the pharmaceutical industry, primarily known for manufacturing and marketing bulk drugs and formulations. The company operates in the pharmaceutical sector, focusing on developing, producing, and selling generic medicines, active pharmaceutical ingredients (APIs), and proprietary products. Natco Pharma has a notable presence in both the domestic and international markets, with a strong portfolio in oncology and specialty pharmaceuticals. In recent years, the company has been involved in various product launches and strategic partnerships to enhance its market reach and product offerings. However, specific recent developments for Natco Pharma are not available in the provided data.
Revenue
For the third quarter of the fiscal year 2026 (Q3FY26), Natco Pharma reported a total income of ₹705.40 crores. This represents a significant decline of 51.8% compared to the previous quarter (Q2FY26), where the total income was ₹1463.00 crores. On a year-over-year basis, the total income increased by 8.3% from ₹651.10 crores in Q3FY25. The data indicates that while there was robust growth in total income compared to the previous year, the quarter-over-quarter performance saw a substantial decrease.
Profitability
Natco Pharma's profitability metrics for Q3FY26 show a profit before tax (PBT) of ₹161.10 crores, which is a steep decline of 73.7% QoQ from ₹613.70 crores in Q2FY26. Year-over-year, PBT fell by 1.6% from ₹163.70 crores in Q3FY25. The tax expense for Q3FY26 stood at ₹20.70 crores, decreasing by 78.4% QoQ and by 33.9% YoY. Consequently, the profit after tax (PAT) for Q3FY26 was ₹151.30 crores, representing a 70.8% QoQ decrease but a 14.3% YoY increase from ₹132.40 crores in Q3FY25. Earnings per Share (EPS) for this quarter were ₹8.46, falling by 70.8% QoQ but rising by 13.9% YoY.
Operating Metrics
The financial data indicates a reduction in total expenses for Q3FY26, amounting to ₹544.30 crores, a 35.9% decline from ₹849.30 crores in Q2FY26. Compared to the same quarter in the previous year, total expenses increased by 11.7% from ₹487.40 crores in Q3FY25. This change in expenses is reflected in the company's profitability and operational efficiency. Despite the QoQ decline in expenses, the YoY growth suggests operational adjustments or changes in the cost structure that have impacted the overall financial performance. The data provided does not include specific financial ratios or detailed operating metrics like P/E ratio, debt-to-equity ratio, or current ratio, which limits a deeper analysis based on the existing information.